GlaxoSmithKline's chronic disease treatment study meets late-stage main goals


April 3 (Reuters) - GlaxoSmithKline plc GSK.L said on Friday its treatment for a chronic inflammatory disease of the nasal passage linings or sinuses met the main goals in a late-stage study.

The treatment, Nucala, was tested in patients who had a history of previous surgery and were in need of further surgery due to severe symptoms or worsening of the condition, the British drugmaker said. (

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Vinay Dwivedi)

((; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Twitter: @JagadeeshAakash;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.